CBI offers prospective collection of plasma samples from patients, cancer gene mutation detection kits, and reagents for efficient isolation of circulating cell-free DNA and RNA from liquid biopsies. Our cfDNA isolation kits have been specifically developed for efficient recovery of small DNA fragments.
Introducing the SubX® Plasma cfDNA Isolation Kit - Liquid Biopsy Made Easy
A method for fast and effective biding of DNA to solid phase matrix in physiological conditions (directly in bio-liquids)
Unbiased isolation of DNA fragments
No dilution of the starting material is required
Request Free Sample (Offer is valid only for US customers untill April 30. If you provide us feedback, we will give you 50% discount for the first purchase.)
The DNA-binding SubX® matrix allows:
• Flexibility. Scaling up of the procedure to 50 ml of starting material or scaling down to extra-low volumes as well as adaptation of the protocol for 96- or 384-well formats
• Efficiency. Separation of cfDNA from the bulk of proteins in a single vortex-spin step without employing chaotropic agents allows you to speed-up the isolation procedure to save time and overall costs
• Adaptability. Effectively bind cell-free DNA of virtually any size ranging from 100 Kbp down to 50 bp therefore extending downstream applications
Cell-free circulating DNA was discovered in 1948 but only recently has begun to attract the widespread attention of researchers. Historically, tumor tissue was considered as the major source of tumor DNA and thus invasive biopsy was the only way of obtaining such materials. Later, it was discovered that dying tumor cells release small pieces of their DNA into the bloodstream. These pieces are called cell-free circulating tumor DNA (ctDNA).
ctDNA has been detected in most types of cancer, even during early stages, suggesting the analysis of ctDNA at every stage of cancer may be used in personalized patient care. Thus, measurement of ctDNA levels in blood and identification of specific mutations in certain genes may also be used for estimation of cancer stage development and prognosis.